ASX cannabis share Cronos has soared 80% in a month. What’s going on?

This cannabis share has been on fire this month…

| More on:
Back view of a man lifting hish hands high in front of hemp plants grown for cannabis.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been a stunning few weeks for the Cronos Australia Ltd (ASX: CAU) share price.

Since this time last month, the medicinal cannabis company’s shares have risen over 80%.

This led to the Cronos Australia share price reaching a record high of 75 cents earlier today.

Why is the Cronos Australia share price on fire this month?

While the company released a positive update last week which boosted its shares, the majority of the gains were made earlier in the month.

The catalyst for that appears to have been a bullish broker note out of Bell Potter.

According to the note from 5 September, the broker initiated coverage on the company’s shares with a buy rating and 60 cents price target.

At the time, the Cronos Australia share price was fetching 46 cents, so this implied potential upside of 30% for investors.

Why is Bell Potter bullish?

Bell Potter explained that its bullish view was based largely on the company’s leadership position in medicinal cannabis distribution. It commented:

Cronos Australia is a medicinal cannabis company that is the market leader in distribution to pharmacies and provides patient consulting services through its clinic business. The key driver for the impressive growth in the past 24 months has been the CanView platform which provides the widest range of medicinal cannabis products compared to competitors (Anspec, Health House).

In addition, Bell Potter points out that Cronos Australia is profitable and even pays a dividend. That makes it the only one of its kind in the Australian cannabis industry. It explained:

We initiate coverage on Cronos with a Buy recommendation. We expect the momentum observed in FY22 to continue into FY23 and translate into strong revenue and earnings growth. Cronos is currently the only profitable dividend paying medicinal cannabis company on the ASX and the valuation does not appear demanding relative to the expected growth.

Though, with the Cronos Australia share price now trading higher than Bell Potter’s valuation, it’s worth considering that it could have peaked for the time being.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Cannabis Shares

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they’re at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here’s why

This medicinal cannabis company has been a rare winner in its field.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Cannabis Shares

Which ASX cannabis share is surging 27% on record quarterly results?

Althea CEO Josh Fegan has declared "a landmark turning point" for the company.

Read more »

little green pharma share price represented by cannabis leaf character jumping cheerfully
Cannabis Shares

Little Green Pharma share price shoots 13% higher after capital raise

There's considerable excitement in the medicinal cannabis space as Australia becomes the world's first market to recognise psychedelics as medicines.

Read more »

An older farmer wearing a checkered shirt and a straw hat stands in a green field of cannabis plants growing up to waist level as he smiles while thinking about the outlook for ASX cannabis shares in FY23
Cannabis Shares

Buying ASX cannabis stocks? Here’s what the Victorian government is considering right now

Victoria became the first state to legalise medicinal cannabis in 2016. Now the government is playing catch-up with other laws.

Read more »

A graphic showing a rising share price in medical cannabis shares
Cannabis Shares

Why did this ASX 300 cannabis share just rocket 12%?

Incannex is going to make its own pharmaceutical-grade psilocybin drug for clinical trials and potential commercial use.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Why did this ASX cannabis share just rocket 46%?

This cannabis share has been given a major boost by regulators...

Read more »